Innovent has lodged a priority review application with China’s NMPA for arcotatug tavatecan after the Phase III G‑HOPE‑001 trial met its primary PFS endpoint in third‑line CLDN18.2‑positive gastric and gastroesophageal junction cancer. The ADC delivered a statistically significant PFS benefit and showed a manageable safety profile, according to Professor Lin Shen. If approved, it would be the first CLDN18.2‑targeting ADC on the market; broader CLDN18.2 research remains active with 100+ ongoing trials.
Innovent Seeks Third‑Line Approval in China for Arcotatug Tavatecan After Phase III PFS Win
Innovent's CLN18.2-targeting ADC
Takeda’s $11.4 billion acquisition of assets from Innovent Biologics is beginning to pay off: Innovent has filed for priority review in China for its antibody‑drug conjugate (ADC) arcotatug tavatecan after a positive Phase III readout.
The ongoing Phase III G-HOPE-001 trial (NCT06238843), run at sites in China and Japan, compared Innovent’s CLDN18.2‑targeting ADC against either irinotecan (Pfizer’s Campto) or an oral combination of trifluridine with the enhancer tipiraci. The study enrolled patients with refractory, locally advanced, unresectable or metastatic CLDN18.2‑positive gastric or gastroesophageal junction adenocarcinoma (G/GEJA) as third‑line therapy.
At the per‑protocol first interim analysis, arcotatug tavatecan produced a statistically significant improvement in progression‑free survival (PFS) among third‑line‑plus patients, meeting the trial’s primary endpoint.
Safety and expert view: Professor Lin Shen, Director of Gastrointestinal Oncology at Beijing Cancer Hospital, commented that the ADC showed a “manageable” safety profile. He said the agent could expand treatment options for refractory patients and help drive wider adoption of precision diagnostics and targeted therapies in gastrointestinal oncology.
How the drug works: Arcotatug tavatecan is a biomarker‑guided ADC engineered to selectively deliver a potent exatecan payload to CLDN18.2‑expressing tumour cells. Innovent says it optimised the conjugate to limit off‑tumour toxicity.
Regulatory and commercial context: Innovent confirmed that China’s National Medical Products Administration (NMPA) has accepted its new drug application for arcotatug tavatecan as a third‑line treatment for CLDN18.2‑positive G/GEJA and will evaluate it under a priority review pathway. Takeda holds rights to the ADC outside China under the October 2025 deal worth $11.4 billion.
If authorised, arcotatug tavatecan would be the first CLDN18.2‑targeting ADC to gain regulatory approval, offering a new option for patients with limited choices and generally poor prognosis in the refractory setting.
Target prevalence and competing therapies: Published data in the Journal of Clinical Oncology report that 35–40% of tumours in unresectable or metastatic G/GEJA demonstrate high CLDN18.2 expression, while Innovent estimates up to ~80% of tumours are CLDN18.2‑positive—differences that likely reflect varying assay methods and positivity thresholds. Arcotatug would not be the first CLDN18.2‑directed therapy to reach patients: Astellas’ Vyloy (zolbetuximab) received US approval in 2024 for use with chemotherapy in HER2‑negative G/GEJ.
According to GlobalData, more than 100 ongoing gastric cancer trials target CLDN18.2, with the greatest number in Phase II, underscoring intense R&D activity around this target.
What's next: Innovent has not yet released full trial data beyond the topline PFS result and safety summary. The NMPA priority review will determine whether the ADC becomes the first CLDN18.2‑targeting conjugate approved in China; clinicians and investors will be watching for detailed efficacy, safety, and biomarker analyses.
Help us improve.
